![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Lupin Limited Mumbai In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Rifaximin, supported by a 'Valid' Certificate of Suitability (CEP) with the number R0-CEP 2020-175 - Rev 00
This Chemical and TSE Type CEP, issued on December 07, 2022, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 2362 associated with this CEP further emphasizes